SCHEMBL2762003

SCHEMBL2762003

CNS(=O)(=O)c1ccc(NC(=O)Nc2cccc(C#N)c2)cc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.68
MEN1 O00255 3/20 0.68
KMT2A Q03164 3/20 0.68
ALDH1A1 P00352 2/20 0.68
RAB9A P51151 3/20 0.67
GAA P10253 2/20 0.67
KCNJ6 P48051 1/20 0.58
KCNJ5 P48544 1/20 0.58
KCNJ3 P48549 1/20 0.58
NPC1 O15118 2/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
ALOX15 P16050 2/20 0.53
CASP7 P55210 1/20 0.53
HSD17B10 Q99714 1/20 0.53
CA12 O43570 1/20 0.52
CA1 P00915 1/20 0.52
CA2 P00918 1/20 0.52
CA9 Q16790 1/20 0.52
IDO1 P14902 2/20 0.51
NSD2 O96028 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6284564 0.84 MAPT (0.72) MAPTMEN1KMT2AALDH1A1RAB9A
SCHEMBL13196624 0.84 CA2 (0.74) MAPTMEN1KMT2AALDH1A1GAA
SCHEMBL2762707 0.83 CA2 (0.64) MAPTMEN1KMT2AALDH1A1CA12
SCHEMBL7248947 0.82 MAPT (1.00) MAPTMEN1KMT2AALDH1A1RAB9A
SCHEMBL30606801 0.82 MAPT (0.87) MAPTMEN1KMT2AALDH1A1RAB9A
SCHEMBL29580531 0.82 MAPT (0.87) MAPTMEN1KMT2AALDH1A1RAB9A
SCHEMBL2761963 0.81 NAMPT (0.68) MAPTMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL2762384 0.81 CA2 (0.65) MAPTMEN1KMT2AALDH1A1KCNJ6
SCHEMBL6282309 0.81 MAPT (0.60) MAPTMEN1KMT2AALDH1A1RAB9A
SCHEMBL4117070 0.81 MAPT (0.80) MAPTMEN1KMT2AALDH1A1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8343963-B2 Sulfamoyl-phenyl-ureido compounds and their use as medicament 4SC AG (DE) 2013-01-01 US disclosed
EP-2391601-A1 SULFAMOYL- PHENYL-UREIDO BENZAMIDINE-DERIVATIVES AS ANTIMALARIAL AGENTS 4SC AG (DE) 2011-12-07 EP disclosed
WO-2010086177-A1 SULFAMOYL- PHENYL-UREIDO BENZAMIDINE-DERIVATIVES AS ANTIMALARIAL AGENTS 4SC AG (DE) 2010-08-05 WO disclosed
US-20100197640-A1 NOVEL SULFAMOYL-PHENYL-UREIDO COMPOUNDS AND THEIR USE AS MEDICAMENT 4SC AG (DE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197640-A1 NOVEL SULFAMOYL-PHENYL-UREIDO COMPOUNDS AND THEIR USE AS MEDICAMENT SLC14A1, UTS2R, UROD MAPT 1172/4885MEN1 2878/4885KMT2A 2192/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.